Skip to content
The Kids Research Institute Australia logo
Donate

Search

Showing results for "clinical trials"

Polymorphisms in key innate immune genes and their effects on measles vaccine responses and vaccine failure in children from Mozambique

Despite an effective vaccine, measles remains a major health problem globally, particularly in developing countries. More than 30% of children show primary...

TLR3 and RIG-I gene variants: Associations with functional effects on receptor expression and responses to measles viru

Measles virus causes severe morbidity and mortality, despite the availability of measles vaccines. Successful defence against viral pathogens requires early...

Toll-like receptor 7 and 8 polymorphisms: Associations with functional effects and cellular and antibody responses to measles virus and vaccine

The functionality and effects of TLR7 and TLR8 polymorphisms on cellular and antibody responses was investigated after the first measles vaccine dose.

Molecular surveillance of true nontypeable haemophilus influenzae: An evaluation of pcr screening assays

Unambiguous identification of nontypeable Haemophilus influenzae (NTHi) is not possible by conventional microbiology. Molecular characterisation of...

Perth researchers to trial bird flu vaccine

Perth researchers have begun a trial to test the effectiveness of a new vaccine to protect against the potentially deadly bird flu.

Trial begins of first vaccine against Ross River Virus

Perth researchers are seeking volunteers to test the effectiveness of a vaccine against the debilitating Ross River Virus.

New findings in the pathogenesis of otitis media

This study was the first to concurrently identify middle ear pathogens in both bacterial biofilm and intracellularly in the middle ear mucosa of children and to identify extensive DNA stranding in the MEF from children with AOM

Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 months

A bivalent, recombinant, factor H-binding protein (rLP2086) vaccine was developed to protect against invasive Neisseria meningitidis serogroup B (MnB) in...

A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults:

Neisseria meningitidis is a leading cause of meningitis and septicaemia, but a broadly-protective vaccine against endemic serogroup B disease is not licensed...